GYANT Unveils New Solution to Manage Demand, Improve Patient Journey for Future COVID-19 Vaccine

AI-powered virtual assistant generates COVID-19 vaccine early momentum with deployment commitments from five health systems

GYANT, the AI-powered virtual assistant company, announced its first-to-market vaccine care navigation tool, GYANT Vaccine, anticipating impending health system strain following emergency use authorization of a COVID-19 vaccine. The solution offers support for each step of the patient journey, from initial inquiry to post-vaccination follow-up.

“With our help, customers are poised to effectively anticipate and manage the vaccine’s deployment whenever it is approved, and play a role in controlled widespread adoption as we seek to overcome this crisis.”

Anticipating the tsunami of inbound patient inquiries, overwhelmed call centers, appointment scheduling demands, and eligibility screening requests as the vaccine becomes available, GYANT Vaccine will virtually guide patients through the entire pre- and post-vaccination process.

Recommended AI News: Facebook Partners With The Namibian Ministry Of Health And Social Services (MOHSS) To Boost Blood Donations In The Country

GYANT Vaccine is built with the patient perspective in mind, prioritizing a seamless experience. The solution anticipates and captures vaccine demand, helping health systems to pre-qualify individuals and facilitate deployment in direct alignment with phased or prioritized availability. By empowering patients to learn about processes and options, screen and assess prioritization, book appointments, and stay in touch with their providers to schedule additional doses and monitor for side effects, GYANT Vaccine adapts to each provider’s changing requirements over the course of the vaccine roll-out.

“Navigating the deployment of the COVID-19 vaccine will be the single biggest challenge healthcare systems face in 2021,” said Stefan Behrens, co-founder and chief executive officer, GYANT. “With our help, customers are poised to effectively anticipate and manage the vaccine’s deployment whenever it is approved, and play a role in controlled widespread adoption as we seek to overcome this crisis.”

Recommended AI News: Capsule8 Strengthens Customer Support and Partnership Leadership

GYANT Vaccine builds on the company’s successful COVID-19 SERA technology, which rapidly helped 25 payer and health system customers and half a million patients screen and triage symptoms to access testing and care. With the addition of Vaccine, GYANT’s AI-powered virtual assistant platform now even more effectively connects the dots across patients’ digital journeys with the existing Front Door (care navigation and triage), Engage (patient outreach) and Clipboard (automated chart population) modules. GYANT Vaccine has already generated overwhelming interest in the market with five health systems signed on to deploy the tool following emergency use authorization of a vaccine.

Recommended AI News: Vision Hill Group Launches VisionTrack to Help Institutional Investors Navigate the Crypto Buy-side